GlassScriptPhysician profile
Jason Lee Massa
NPI 1841636156
$5,538.22
in general payments reported to CMS, 2019-2025
15 companies · $3,074 in 2025
The $3,074 reported for 2025 was more than what 79% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $252 · 2020: $362 · 2021: $221 · 2022: $385 · 2023: $612 · 2024: $631 · 2025: $3,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,042 · Education: $1,275.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,041.91 |
| Education | $1,275.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $1,609.92 | 2023-2025 | Crexont, Ongentys 50mg Capsules 30, Rytary |
| Abbvie INC. | $1,007.71 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $980.11 | 2024-2025 | Ingrezza |
| Boston Scientific Corporation | $754.03 | 2019-2023 | |
| Teva Pharmaceuticals USA, INC. | $401.57 | 2023-2025 | Austedo Xr, Austedo, Austedo Xr |
| Allergan, INC. | $302.10 | 2020-2021 | |
| Kyowa Kirin, INC. | $145.93 | 2020-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $88.84 | 2025 | Xeomin, Inbrija |
| Lundbeck LLC | $67.52 | 2025 | Vyepti |
| Csl Behring | $57.54 | 2025 | Hizentra |
| Ucb, INC. | $40.50 | 2025 | Briviact |
| Acadia Pharmaceuticals INC | $30.04 | 2025 | Nuplazid |
| Lilly USA, LLC | $23.92 | 2025 | Kisunla |
| Scilex Pharmaceuticals INC. | $16.90 | 2024 | |
| Bausch Health US, LLC | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Massa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.